Israel-based medical device company Momentis Surgical has received the US Food and Drug Administration (FDA) 510(k) approval for its Anovo robotic surgical platform.
The Anovo system is an endoscopic instrument control system indicated for single-site, abdominal access ventral hernia repair.
The system is designed to assist in the accurate control of the Anovo Arms during single-site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.
It works by imitating surgeons’ natural humanoid movements with shoulder, elbow, and wrist joints, enhancing their freedom of movement within the abdomen.
Also, the system allows placing multiple instruments in the body through a single portal and its 360-degree articulation avoids obstacles and provides optimal access.
Unlike traditional robotic platforms, the Anovo system can be accessed in any operating room (OR), and its open console facilitates improved communication with the OR team, said Momentis.
Imelda Hospital in Bonheiden, Belgium, surgery head Tim Tollens performed a series of ventral hernia procedures using the Anovo system.
Tollens said: “This FDA authorisation represents a significant advancement in the world of robotic surgery by making Anovo a versatile robotics platform for multi-specialty use.
“I have experience with other robotic systems and the Anovo platform is not only potentially better for my patients by reducing the number of incisions, but also incredibly easy for me and my OR staff to use.
“The average docking time for the robot was under 2 minutes, which is an order of magnitude faster than other robotic systems.”
According to Momentis, Anovo is the world’s first single-port robotics platform approved by the FDA to perform ventral hernia procedures.
The robotic system allows for single port procedures with multiple flexible instruments to enable less invasive and less traumatic outcomes for the tissue.
It features miniature humanoid-shaped robotic arms that provide human-level dexterity, multi-planar flexibility and 360 degrees of articulation.
The biomimetic instruments are designed to recreate the motions and capabilities of a surgeon’s arms, with shoulder, elbow, and wrist joints, said the medical device company.
Momentis Surgical CEO and co-founder Dvir Cohen said: “Leveraging the clinical achievements of our Anovo platform in gynaecology and the connections we established with leading medical centres worldwide, we have seized the opportunity to expand to general surgery for our groundbreaking technology.
“Due to its size and mobility, our system can be used both in hospitals and outpatient settings, where most hernia surgeries can be performed, but are not currently, because of the limitations of existing robotic platforms.
“Anovo’s unique features allow surgeons and patients access to robotic procedures outside the hospital by offering robotic technology to ambulatory surgical centres.”
